Carisoprodol

Selected References:

- Bailey DN, Briggs JR. 2002. Carisoprodol: an unrecognized drug of abuse. Am J Clin Pathol. 117(3):396-400. \
- Briggs GG, et al. 2008. High dose carisoprodol during pregnancy and lactation. Ann Pharmacother. 42(6):898-901.
- Grizzle TB, et al. 1995. Carisoprodol: reproductive assessment by continuous breeding in Swiss mice. Fundam Appl Toxicol. 24(1):132-139.
- Heinonen OP, et al. 1977. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Sciences Group. 357-65.
- Nordeng H, et al. 2001. Transfer of carisoprodol to breast milk. Ther Drug Monit. 23:298-300.
- Nostrum Laboratories. 2021. Carisoprodol prescribing information. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ab22f1be-16c8-45b6-adaf-09e08bf7a545&type=display. Accessed 10 August 2026.
- Prescribing Label for Soma. 2019. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6297cf20-830a-11dc-94c8-0002a5d5c51b. Accessed 10 August 2026.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de abril de 2026.

Carisoprodol

Selected References

- Balevic SJ, et al. 2024. Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With

COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial. JAMA Netw Open. 7(4):e247615.

- Bhimraj A, et al. 2025. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clin Infect Dis. 81(Supplement_3):i1-i5.
- Chin A, et al. 2025. Recommendations for the Use of Disease-Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review. Arthritis Care Res (Hoboken). 77(10):1273-1281.
- Dernoncourt A, et al. 2023. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: Insights from an analysis of the World Health Organization pharmacovigilance database (VigiBase®). BioDrugs. 37(1):73-87.
- E.R. Squibb and Sons, L.L.C. (Last updated: October 30, 2023). Orencia drug label. Source: National Library of Medicine. Available at https://dailymed.nlm.nih.gov/dailymed/druginfo.cfm?setid=0836c6ac-ee37-5640-2fed-a3185a0b16eb. Accessed 31 July 2026.
- Ghalandari N, et al. 2022. Reported congenital malformations after exposure to non-tumour necrosis factor inhibitor biologics: A retrospective comparative study in EudraVigilance. Br J Clin Pharmacol. 88(12):5378-5388.
- Kumar M, et al. 2015. Pregnancy outcomes following exposure to abatacept during pregnancy. Semin Arthritis Rheum. 45(3):351-356.
- Makol A, et al. 2011. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. Drugs. 71(15):1973-1987.
- Nadig N, et al. 2025. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept. Clin Infect Dis. 81(Supplement_3):i17-i21.
- Ojeda-Uribe M, et al. 2013. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol. 32(5):695-700.
- Ostensen M, Förger F. 2011. Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol. 23(3):293-298.
- Partlett R, Roussou E. 2011. The treatment of rheumatoid arthritis during pregnancy. Rheumatol Int. 31(4):445-449.
- Pham T, et al. 2012. Abatacept therapy and safety management. Joint Bone Spine. 79 Suppl 1:3-84.
- Saito J, et al. 2019. Abatacept concentrations in maternal serum and breast milk during breastfeeding and an infant safety assessment: a case study. Rheumatology (Oxford). 58(9):1692-1694.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de abril de 2026.

Carisoprodol

Selected References:

- Acs N, et al. 2009. Senna treatment in pregnant women and congenital abnormalities in their offspring- a population-based case-control study. Reproductive Toxicology Jul 28(1):100-104.
- Avery GS, et al. 1972. Lactulose: a review of its therapeutic and pharmacologic properties with particular reference to ammonia metabolism and its mode of action in portal systemic encephalopathy. Drugs 4:7-48.
- Baldwin WF. 1963. Clinical study of senna administration to nursing mothers: assessment of effects on infant bowel habits. Canadian Medical Association Journal 89:566-568.
- Body C, et al. 2016. Gastrointestinal Diseases in Pregnancy: Nausea, Vomiting, Hyperemesis Gravidarum, Gastroesophageal Reflux Disease, Constipation, and Diarrhea. Gastroenterol Clin North Am. 45(2):267-83.
- Concin N, et al. 2008. Mineral oil paraffins in human body fat and milk. Food and Chemical Toxicology 46(2):544-552.
- Danhof IE. 1982. Pharmacology, toxicology, clinical efficacy, and adverse effects of calcium polycarbophil, an enteral hydrosorptive agent. Pharmacotherapy 2:18-28.
- Friedrich C, et al. 2011. Lack of excretion of the active moiety of bisacodyl and sodium picosulfate into human breast milk: an open-label, parallel group, multiple dose study in healthy lactating women. Drug Metab Pharmacokinet 26(5):458-464.
- Gattuso JM, Kamm MA. 1994. Adverse effects of drugs used in the management of constipation and diarrhoea. Drug Safety 10:47-65.
- Hagemann TM. 1998. Gastrointestinal medications and breastfeeding. Journal of Human Lactation 14:259-262.
- Rude RK, Singer FR. 1981. Magnesium deficiency and excess. Annual Review of Medicine 323:245-259.
- Samavati R, et al. 2017. Herbal laxatives and antiemetics in pregnancy. Reprod Toxicol. 72:153-158. doi: 10.1016/j.reprotox.2017.06.041
- Schindler AM. 1984. Isolated neonatal hypomagnesaemia associated with maternal overuse of stool softener. Lancet 2:822.
- The WHO Working Group, Bennet PN (ed). 1988. Drugs and Human Lactation. Elsevier, Amsterdam, New York, Oxford, 88-89.
- Trottier M, et al. 2012. Treating constipation during pregnancy. Canadian Family Physician 58:836-838.
- Werthmann MW, Jr., Krees SV. 1973. Quantitative excretion of Senokot in human breast milk. The Medical Annals of the District of Columbia 42(1):4-5.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de abril de 2026.

Carisoprodol

Selected References:

- Amir LH, et al. 2006. A case-control study of mastitis: nasal carriage of Staphylococcus aureus. BMC Family Practice; 7:57.
- Behari P, et al. 2004. Transmission of methicillin-resistant Staphylococcus aureus to preterm infants through breast milk. Infect Control Hosp Epidemiol; 25(9):778-780.
- Briggs G. 2005. Drugs in Pregnancy and Lactation, a reference guide to fetal and neonatal risk. 7th Ed. Baltimore, MD: Williams & Williams.
- De Rose, et al. 2023. Staphylococcal infections and neonatal skin: data from literature and suggestions for the clinical management from four challenging patients. Antibiotics; 12(4):632.
- Elston DM. 2007. Community acquired methicillin-resistant Staphylococcus aureus. J Am Acad Dermatol; 56(1):1-16.
- Farsimadan M, Motamedifar M. 2020. Bacterial infection of the male reproductive system causing infertility. J Reprod Immunol; 142:103183.
- Frank A, et al. 1999. Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children. Ped Inf Dis J; 18:993-1000.
- Gastelum DT, et al. 2005. Transmission of community-associated methicillin-resistant Staphylococcus aureus from breast milk in the neonatal intensive care unit. Pediatr Infect Dis J; 24(12):1122-1124. 2
- Goto H, et al. 2003. Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics. Jpn J Antibiot. 58(3):326-58.
- Inukai K, et al. 2025. Infective endocarditis caused by methicillin-resistant Staphylococcus epidermidis in the infant of a mother with diabetes: a case report. Tokai J Exp Clin Med; 50(1): 21-24.
- Kawada M, et al. 2003. Transmission of Staphylococcus aureus between healthy, lactating mothers and their infants by breastfeeding. J Hum Lact; 19(4):411- 417.
- Kriebs JM. 2016. Staphylococcus Infections in Pregnancy: Maternal and Neonatal Risks. J Perinat Neonatal Nurs; 30(2):115-23.
- Laibl V, et al. 2005. Clinical Presentation of Community-Acquired Methicillin-Resistant Staphylococcus aureus in Pregnancy. Obstet Gynecol; 106 (3):461- 5.
- Leshem E et al. 2012. Transmission of Staphylococcus aureus from mothers to newborns. Pediatr Infect Dis J; 31(4):360-3.
- Lazenby GB, et al. 2012. Methicillin-resistant Staphylococcus aureus colonization among women admitted for preterm delivery. Am J Obstet Gynecol; 206(4):329.e1-5.
- Maglio D, et al. 2005. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program. Clin Ther; 27(7):1032-42.
- Piva S, Mariella J, et al 2021. Epidemiologic case investigation on the zoonotic transmission of Staphylococcus

aureus infection from goat to veterinarians. Zoonoses Public Health; 68(6):684-690.

- Price M, et al. 1998. Prevalence of methicillin-resistant Staphylococcus aureus in a dermatology outpatient population. South Med J; 91:369-71.
- Salmanov AG, et al. 2021. Bacterial infection causes of pregnancy loss and premature birth in the women in Ukraine. Wiad Lek; 74(6):1355-1359.
- Saravolatz L, et al. 1982. Methicillin-resistant Staphylococcus aureus: epidemiologic observations during a community-acquired outbreak. Ann Intern Med; 96:11-16.
- Sheffield JS. 2013. Methicillin-resistant Staphylococcus aureus in obstetrics. Am J Perinatol; 30(2):125-9.
- The Centers for Disease Control and Prevention (CDC). 2024. About Staph food poisoning. https://www.cdc.gov/staph-food-poisoning/about/index.html [Accessed 4/2026].
- The Centers for Disease Control and Prevention (CDC). 2026. Preventing Methicillin-resistant Staphylococcus aureus (MRSA): Prevent MRSA in higher risk settings. https://www.cdc.gov/mrsa/prevention/index.html#cdc_prevention_when_traveling-prevent-mrsa-in-higher-risk-settings [Accessed 4/2026].
- The Centers for Disease Control and Prevention (CDC). 2024. Strategies to prevent hospital-onset Staphylococcus aureus bloodstream infections in acute care facilities. https://www.cdc.gov/staphylococcus-aureus/hcp/prevent-in-acute-care-facilities/index.html [Accessed 4/2026].
- Tong SY, et al. 2015. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev; 28(3):603-61.
- Younger Meek, American Academy of Pediatrics, et al. 2022. Policy Statement: Breastfeeding and the Use of Human Milk. Pediatrics; 150(1):e2022057988.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de abril de 2026.

Carisoprodol

Selected References:

- Abraham K, 2021. Maternal and Perinatal Outcomes of Influenza in Pregnancy after Treatment with Oseltamivir. J Glob Infect Dis. 13(1):20-26.
- American College of Obstetricians and Gynecologists (ACOG). 2018. Committee Opinion No. 753: Assessment and treatment of pregnant women with suspected or confirmed influenza. Obstet Gyn, 132(4):e169-e173.
- Antiviral drugs for influenza for 2023-2024. 2023. Med Lett Drugs Ther. 65(1689):177-182.
- Aoki FY, et al. 2013. The use of antiviral drugs for influenza: A foundation document for practitioners. Can J Infect Dis Med Microbiol, 24(Suppl C):1-15.
- Beau A-B, et al. 2014. Safety of oseltamivir during pregnancy: a comparative study using the EFEMERIS database. BJOG; 121(7):895-900.
- Centers for Disease Control and Prevention. 2011. Antiviral agents for the treatment and chemoprophylaxis of influenza. MMWR; 60(No. RR-1):1-25.
- Chambers CD, et al, OTIS Collaborative Research Group. 2019. Oseltamivir use in pregnancy: Risk of birth defects, preterm delivery, and small for gestational age infants. Birth Defects Res; 111(19):1487-1493.
- Chow EJ, et al. Clinical Effectiveness and Safety of Antivirals for Influenza in Pregnancy. Open Forum Infect Dis; 8(6):ofab138.
- Cizeron A, et al. 2021. Low rate of oseltamivir prescription among adults and children with confirmed influenza illness in France during the 2018-19 influenza season. J Antimicrob Chemother; 76(4):1057-1062.
- Dunstan H, et al. 2014. Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study. BJOG; 121(7):901-906.
- Fodor E, et al. 2023. An Observational Study on the Pharmacokinetics of Oseltamivir in Lactating Influenza Patients. Clin Pharmacol Ther; 115(2):318-323.
- Graner S, et al. 2017. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study. BMJ; 356:j629.
- Greer LG, et al. 2010. Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications. Obstet Gynecol; 115(4):711-716.
- Greer LG, et al. 2011. Pharmacokinetics of oseltamivir in breast milk and maternal plasma. Am J Obstet Gynecol; 204: 524.e1-4.
- Laibl VR and Sheffield JS. 2005. Influenza and pneumonia in pregnancy. Clinics in Perinatology; 32:727-738.
- Lian J, et al. 2022. Neonatal outcomes after neuraminidase inhibitor use during pregnancy: A meta-analysis of cohort studies. Br J Clin Pharmacol; 88(3):911-918.
- Mancilla-Galindo J, et al. 2021. All-cause mortality among patients treated with repurposed antivirals and antibiotics for COVID-19 in Mexico City: A real-world observational study. EXCLI J; 20:199-222.
- Saito S, et al. 2013. Outcomes of infants exposed to oseltamivir or zanamivir in utero during pandemic (H1N1) 2009. Am J Obstet Gynecol; 209 (2): 130.e1-9.
- Siston A, et al. 2010. Pandemic 2009 influenza A (H1N1) virus illness among pregnant women in the United States. JAMA; 3030(15):1517-1525.
- Svensson T, et al. 2011. Birth outcomes among women exposed to neuraminidase inhibitors during pregnancy. Pharmacoepidemiol Drug Saf; 20(10): 1030-1034.
- Tanaka T, et al. 2009. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ; 181(1-2):55-58.
- The Centers for Disease Control and Prevention (CDC). 2025. Treating flu with antiviral drugs. https://www.cdc.gov/flu/treatment/antiviral-drugs.html.
- The CDC. 2026. Influenza antiviral medications: Summary for

clinicians. https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html [Accessed April 2026].

- Van Bennekom CM, Kerr SM, Mitchell AA. 2019. Oseltamivir exposure in pregnancy and the risk of specific birth defects. Birth Defects Res; 111(19):1479-1486.
- Wentges-van Holthe N, et al. 2008. Oseltamivir and breastfeeding. Int J Infect Dis; 12:451.
- Wollenhaupt M, et al. 2014. The safety of oseltamivir in pregnancy: an updated review of post-marketing data. Pharmacoepidemiol Drug Saf; 23(10):1035-1042.
- Xie H-Y, et al. 2013. Infant outcomes among pregnant women who used oseltamivir for treatment of influenza during the H1N1 epidemic. Am J Obstet Gynecol; 208:293.e1-7.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de abril de 2026.